利妥昔单抗治疗与结缔组织病相关的间质性肺疾病急性加重。
Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease.
机构信息
Pulmonology Department, Hospital Recoletas Campo Grande, Valladolid, Spain
Pulmonology Department, Hospital Recoletas Campo Grande, Valladolid, Spain.
出版信息
RMD Open. 2023 Sep;9(3). doi: 10.1136/rmdopen-2023-003479.
BACKGROUND
Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease.
METHODS
We present a series of four cases in which administration of rituximab was associated with appropriate clinical, radiological and functional progress.
RESULTS
The four patients were alive 30 days after discharge following their exacerbation.
CONCLUSIONS
Given the speed of action, safety and efficacy profile observed for rituximab, we believe that this agent should be further investigated in clinical trials so that it could be included in the daily clinical management of this severe condition.
背景
间质性肺疾病急性加重（AE-ILD）是一种严重的并发症，预后不良。没有临床试验支持利妥昔单抗用于与结缔组织疾病相关的 AE-ILD。
方法
我们报告了四例病例，其中利妥昔单抗的应用与适当的临床、影像学和功能进展相关。
结果
在加重后，四名患者在出院后 30 天仍然存活。
结论
鉴于利妥昔单抗的作用速度、安全性和疗效特征，我们认为应该在临床试验中进一步研究该药物，以便将其纳入这种严重疾病的日常临床管理中。
Zotero 插件